Both obesity rates and antidepressant use have escalated in the last 20 years. Most people who start antidepressant treatment discontinue it on their own. Meanwhile, obesity rates continue to increase. To test the hypothesis that antidepressant use is a risk factor for obesity, even after long-term discontinuation, we developed a novel animal paradigm consisting of short-term exposure to stress and antidepressants, followed by long-term high-fat diet. We show here that recurrent restraint stress (RRS)-related weight loss is recovered 2 weeks after the end of stress in young growing rats receiving a high-fat diet. It is noteworthy that animals that received short-term antidepressant treatment with either imipramine or fluoxetine during 7 days of RRS showed behavioral evidence of antidepressant effects. When exposed to a high-fat diet after stress and when antidepressant treatment had ended, the animals had significant increases in caloric intake, body weight (BW) and size from 17 to 22 weeks following antidepressant discontinuation when compared with (control) RRS animals treated with saline and fed with a high-fat diet. These data are consistent with the previously described phenomenon of time-dependent sensitization, and support the notion that enduring effects of short-term antidepressant treatment become manifest on a long-term basis after antidepressant discontinuation, during conditions of high stress followed by high-fat intake. Analyses of open field and body size measurements obtained in a small subset of animals show that animals previously exposed to antidepressant had no deficits in locomotor activity and were larger. Antidepressant exposure may therefore be a covert, insidious and enduring risk factor for obesity, even after discontinuation of antidepressant treatment. Our data support the concept of persistent, long-term effects of pharmacological–environment interactions on BW regulation.

Keywords: antidepressant; diet; restraint stress; body weight; body size; behavior

Introduction

Major depressive disorder (MDD) is a serious public health problem. Currently, the point prevalence of MDD is ~4–7%, and the lifetime prevalence estimate ranges from 15 to 20%.1-2 MDD is the leading cause of disability measured in years lost because of disability, and the largest single cause of nonfatal disease burden in Australia.3 It will become the second leading contributor to global burden of disease by the year 2020 (disability-adjusted life year).4 Approximately 59% of individuals with MDD seek help for their condition, and 35% receive medication or psychological treatment.5 According to the Canadian Community Health Survey, the prevalence of antidepressant use over a period of 12 months between 2001 and 2002 was estimated at 5.8%.5

MDD is a common complex disorder that affects ~121 million people worldwide. In the United States, the economic burden of MDD is in the order of $100 billions per year, with workplace costs being the largest component.6 Antidepressant dispensing has increased substantially during the last two decades in Western countries. In the United States, antidepressants are prescribed to 27 million people and they are the most frequently prescribed class of medication.7-8 In the United Kingdom, France and Australia, antidepressant prescriptions have increased substantially since the early 1990s with the entry of selective serotonin reuptake inhibitors (SSRIs) in the marketplace.9-11

Studies examining weight gain during long-term SSRI treatment have reported inconsistent results. The results of a large, cross-sectional study based on the General Electric Medical Records Database of MDD patients treated with antidepressant
Long-term BW outcomes of antidepressant-environment interactions
C Mastronardi et al

Molecular Psychiatry

266

monotherapies for at least 1 year suggested differences in the proportion of patients who gained at least 7% of their body weight (BW) during treatment. The highest percentage of patients with weight gain was associated with mirtazapine (26%), followed by the SSRIs (16–19%). Antidepressant treatment can be effective in MDD, but compliance is low: in a large European study of 7525 patients, 56% abandoned treatment within 4 months.

It is generally accepted that the side effects such as weight gain can adversely affect adherence to therapy, but according to Bulloch and Patten,6 the main reason for non-adherence was forgetting (74.5% of responders), followed by ‘felt better’ (10.7%); side effects were reported as the fourth reason (5.9%). It is commonly stated that patients return to their previous weight after they stop taking antidepressants, but this assumption is not evidence based.

To complicate matters, clinical and animal weight data during antidepressant treatment have been difficult to integrate because they appear to support divergent effects; a large body of studies have supported that administration of several antidepressants result in failure to gain weight or ‘paradoxical’ weight loss in rats, especially at high doses. Consequently, animal paradigms that help close some of these gaps could significantly expand our understanding of the interface between obesity and MDD. There is a strong body of translational work that uses rodents to study the biology of depression and antidepressants. These studies have shown that a mechanism of action of antidepressants is to promote neurogenesis in the adult rat hippocampus. Animal models of depression have included stress paradigms (such as uncontrollable stress, chronic mild stress and repeated restraint stress (RRS)) that have been shown to decrease cell proliferation in the hippocampus, and administration of antidepressants can block this downregulation of cell proliferation.

The use of antidepressants has grown dramatically since the late 1980s with the advent of the selective monoamine reuptake inhibitors. Vast numbers of people are exposed to antidepressants on a short-term basis, as long-term compliance is not usually achieved. Such increased exposure to even short courses of antidepressant drugs temporally coincides with the emerging epidemic of obesity that is faced by developed countries. Could the current dramatic increase in obesity be attributed at least in part to exposure to antidepressants? It has been previously demonstrated that the effects of drugs may continue to increase over time, even after a single dose and as drug levels decrease: this intriguing phenomenon is known as drug tolerance (TDS).

We have hypothesized that TDS, which has been described during short-term antidepressant treatment, may apply to weight regulation after exposure to antidepressants. To test this hypothesis, we developed an animal paradigm that combines RRS and behaviorally effective, short-term antidepressant treatment, followed by long-term high-fat diet. This mimics a clinical situation experienced by millions of people: stress/depression is associated with short-term exposure to antidepressants and with long-term ingestion of high-fat diets. In such a paradigm, we tested the specific hypothesis that even short-term exposure to antidepressants represents a long-term risk factor for obesity, manifested protractedly when unmasked by environmental factors, such as high-fat diet.

Materials and methods

Animals

All procedures were performed under established guidelines of humane care and use of rats, and were approved by the University of Miami Institutional Animal Care and Use Committee, and by the Australian National University Ethics Committee. Upon arrival, virus- and antibody-free young adult male Sprague-Dawley rats (Harlan, Indianapolis, IN, USA) were housed at 24°C and 12 h light/dark schedule (lights on from 0600 to 1800 h) in a stress-free environment and divided into two studies: (1) chronic antidepressant treatment and (2) stress, antidepressant and diet (hereafter, stress-antidepressant-diet study).

Chronic antidepressant treatment study

Young growing rats (150–200 g) were housed two per cage in a stress-free environment for at least 5 days before the initiation of experimental procedures. Rats were randomly assigned to two experimental groups: control (0.9% saline; Hospira, Lake Forest, IL, USA), n = 10, and fluoxetine 10 mg (SSRI, Sigma-Aldrich, St Louis, MO, USA), n = 10. Animals received daily 0.5 ml intraperitoneal injections of either 0.9% saline or fluoxetine 10.0 mg kg⁻¹ dissolved in 0.9% saline, for 5 weeks. Dose and treatment duration were based on previous reports. BW was measured weekly.

Stress-antidepressant-diet study

Rats (200–230 g) were housed one per cage (11" wide × 8.5" height × 14.5" long). Food intake (FI) and BW were measured several times a week starting one day after arrival (experimental day 1). Rats were given ad libitum access to food and water, except during the RRS sessions. This experiment lasted 177 days.

Rats were randomly assigned to two main groups: (1) non-restrained control (non-RRS) group (n = 26) and (2) restrained (RRS) group (n = 38). Animals in the non-RRS group were not injected or restrained, and this group comprised two subgroups: (i) NR-CC (n = 13), comprising non-RRS animals fed with regular chow diet throughout the whole experiment; and (ii) NR-CF (n = 13), comprising non-RRS animals fed with chow diet until day 11, and fed with adjusted fat diet thereafter (TD95217; Harlan, Saint Louis, MO, USA).

Animals in the RRS group were subjected to RRS as described below, and received adjusted fat diet (TD95217; Harlan) after day 11. The RRS group...
comprised two subgroups: (i) R-C group (n = 13), comprising RRS animals that received once daily intraperitoneal injection of 0.5 ml of saline (0.9% NaCl; Hospira); and (ii) R-AD group (n = 25), comprising RRS plus antidepressant-treated animals receiving daily intraperitoneal injection of antidepressants for 7 days during the RRS period. Those animals received imipramine (Sigma-Aldrich) 10 mg kg⁻¹ (R-IMI, n = 13) or fluoxetine (Sigma-Aldrich) 10 mg kg⁻¹ (R-FLX, n = 12).

**Repeated restraint stress.** We used flat-bottom clear acrylic restrainers (20.3 x 8.3 cm) (Cat no. 544-RR; Plas Labs, Lansing, MI, USA). RRS sessions occurred during the period of 0900 to 1600 h and lasted 6 h each; they occurred for 7 consecutive days (days 5–11).

**BW and FI.** During the RRS period, BW and FI were measured daily in all animals; BW gain was calculated as the area under the BW curve for non-RRS (n = 26) or RSS (n = 38) groups between days 5 and 11 (Figure 2b). After the restraining period, BW and FI were recorded three times per week until the end of the study at day 177.

**Determination of absolute cumulative caloric intake:** FI was assessed by calculating the weight difference of the food pellets remaining on the cage top between two consecutive determinations. The amount of food consumed was multiplied by its respective caloric content (3.36 kcal g⁻¹ for the regular chow and 4.3 kcal g⁻¹ for the adjusted fat diet). The mean cumulative caloric intake was calculated separately for the restraint period for the non-RRS and the RRS groups. The cumulative intake during the post-restraint period (between days 12 and 177) was plotted as a function of time for the two major restrained groups, namely R-C and R-AD.

**Daily caloric intake:** Daily caloric intake was calculated between days 133 and 163, a period including a total of 14 periods. Individual FI increments were converted into daily caloric intake by dividing the total amount of calories determined between two consecutive measurements by the day interval (2 or 3 days). Those individual caloric intake values were averaged for each period for each experimental group (R-C and R-AD).

**Linear growth, fat mass and behavior.** Body and bone length and locomotor activity were determined in a subset of rats (R-C, n = 5; R-IMI, n = 5; and R-FXT, n = 4).

**Body measurements:** Ano-nasal length was determined weekly (four times) between days 133 and 150.

**Bone measurements:** At the end of the study (day 177), rats were euthanized and their left hind legs were also dissected and heated for 2 h at 80°C in a solution containing 3 ml ammonia solution (7N in methanol) and 25 ml of water to facilitate bone dissection. Lengths of dissected femurs and tibias were measured with a caliper.

**Fat mass:** At the end of the study (day 177), rats were euthanized and epididymal fat pads were dissected and their fresh weights were obtained.

**Locomotor activity:** During the post-restraint period (14–67 days), a subset of rats (R-C, n = 5 and R-AD, n = 9) was submitted to 7 weekly 60 min open field test sessions (between 1400 and 1600 h). Animals were individually placed in clear acrylic boxes (40.64 x 40.64 cm) equipped with Digiscan activity monitors (Omnitech Electronics, Columbus, OH, USA) with infrared light-sensitive detectors situated 2.5 cm apart on two perpendicular walls. Located along the opposing wall were infrared light beams directed at the detectors. One count of horizontal activity was registered each time the animal intercepted the beam. The total distance (TD) was obtained as horizontal activity counts and the center distance (CD) was obtained as horizontal activity counts in the center of the box. In each session, TD, CD and the ratio CD/TD, used as an index of anxiety, were calculated for the R-C and the R-AD groups. Their means were subsequently averaged along the seven sessions.

**Statistical analysis**
Differences among ≥3 groups were analyzed by one-way analysis of variance followed by the Student–Neuman–Keuls multiple comparison test for unequal replications. Differences between two groups were analyzed by ‘t’ test or Mann–Whitney test when appropriate. The significance level for each of these effects was set at P < 0.05. All statistical analyses were performed using GraphPad Prism 5.00 (GraphPad Software, La Jolla, CA, USA).

**Results**

**Effects of chronic antidepressant treatment on BW**
Stress-free animals receiving regular chow and treated with chronic administration of fluoxetine 10 mg kg⁻¹ for 5 weeks had lower weight when compared with animals treated with saline (mean ± s.e., 336.7 ± 3.8 g for saline and 312.0 ± 3.7 g for fluoxetine, P < 0.0001).

**Effects of stress-antidepressant-diet paradigm**
Figure 1a shows BW changes for all the five groups during the entire duration of the stress-antidepressant-diet study.

**Acute effects of RRS.** RRS sessions were performed for 7 consecutive days (days 5–11); during the RRS sessions, rats that were submitted to RRS ingested less calories (mean ± s.e., 672.6 ± 9.5 and 753.1 ± 15.7 kcal, respectively, for RRS and non-RRS groups, P < 0.0001, Figure 2a) and gained significantly less weight (1486.0 ± 6.4 g × day for RRS and 1592.0 ± 13.5 g × day for non-RRS, P < 0.0001, Figure 2b) when compared with control non-stressed animals.

**Fat diet.** Adjusted fat diet was initiated on study day 11 and caused non-stressed animals (NR-CF) to...
Long-term BW outcomes of antidepressant–environment interactions
C Mastronardi et al.

become heavier than those receiving regular chow (NR-CC) (503.0 ± 8.5 and 477.4 ± 6.5 g, respectively, $P=0.025$).

Post-stress recovery period. In the immediate post-stress period, stressed and non-stressed animals fed with high-fat diet had similar absolute caloric intake. RSS animals that received saline (R-C) and fed with high-fat diet achieved full weight recovery, and their weights at day 26 were not significantly different from those of non-stressed animals (NR-CF) receiving fat diet (328.0 ± 2.7 and 336.8 ± 4.8 g, respectively, $P=0.1$). Late in the post-stress recovery period (133–163 days), antidepressant-treated rats (R-AD) became heavier than R-C (Figure 1b, 498.0 ± 2.7 g for R-FXT, 490.4 ± 3.06 g for R-IMI and 477.8 ± 2.85 g for R-C, $P<0.001$ for R-FXT and R-C; and $P<0.01$ for R-IMI and R-C) and had significantly higher caloric intake when compared with the R-C group (Figures 3a and b, 70.9 ± 1.3 for R-AD and 66.0 ± 1.0 for R-C, $P=0.006$). During this period both R-AD and R-C groups were fed with high-fat diet.

Linear growth, fat mass and behavior.

Linear growth: Compared with the non-treated RSS animals, antidepressant-treated RSS animals had larger body size (Figure 3c, 27.3 ± 0.2 cm for R-AD (n = 9) and 26.0 ± 0.4 cm for R-C (n = 5), $P=0.009$), longer femur (Figure 3d, 4.2 ± 0.01 cm for R-AD and 4.1 ± 0.03 cm for R-C, $P=0.01$) and tibia (Figure 3e, 4.5 ± 0.02 cm for R-AD and 4.4 ± 0.03 cm for R-C, $P=0.004$).

Epididymal fat pad measurements: As expected, fat diet increased total body fat content as measured by the fresh weight of epididymal fat pads (12.6 ± 0.7 g for NR-FC and 7.4 ± 1.0 g for NR-CC, $P=0.001$) and epididymal fat pad/BW ratios [23.3 ± 0.9 × 10⁻³ for NR-FC and 14.9 ± 1.8 × 10⁻³ for NR-CC, $P=0.0003$], but these parameters were not significantly different between stressed and non-stressed animals (12.8 ± 0.7 g for RRS and 11.9 ± 1.7 g for non-RRS, $P=0.53$; 23.4 ± 0.9 × 10⁻³ for RRS and 22.8 ± 2.4 × 10⁻³ for non-RRS, $P=0.8$).

Locomotor Activity: A subset of antidepressant-treated animals was tested for locomotor activity and they showed higher locomotor activity reflected both as TD (Figure 4a, 4011.0 ± 187.4 cm for R-AD and 2824.0 ± 324.7 cm for R-C, $P=0.003$) and CD (Figure 4b, 1375.0 ± 58.8 cm for R-AD and 779.9 ± 66.3 cm for R-C, $P<0.0001$), and the ratio CD/TD suggests that RSS animals treated with antidepressants were less anxious in the open field test in comparison with non-treated RSS animals (Figure 4c, 0.4 ± 0.01 for R-AD and 0.3 ± 0.01 for R-C, $P=0.004$).

Discussion

We show here that during the course of a stress paradigm (restraint), short-term exposure to antidepressants decreases the depressive and anxiety behavioral correlates of stress. However, that short exposure to antidepressants is associated with
significant body size and weight gain 122 days after discontinuation of antidepressant treatment in the context of a high-fat diet. We also show that a high-fat diet leads to correction of stress-induced weight loss in the absence of antidepressant treatment. These data suggest that exposure to antidepressants is a long-term risk factor for weight gain and obesity, even after antidepressant treatment is discontinued for a long time.

The relationship of antidepressant treatment and weight gain needs to be carefully examined. Clinically, weight gain is a common occurrence during both acute and long-term treatment with antidepressants, and it is a major problem for two reasons: (1) depressed patients are already at increased risk of cardiovascular disease, and weight gain could worsen that risk; and (2) weight gain is a cause of decreased antidepressant treatment compliance, resulting in treatment dropout. In adults, pooled analyses showed that SSRI treatment induces short-term weight loss, but long-term weight gain. There is still controversy of whether weight gain is mechanistically related to clinical improvement or if it is merely an undesirable side effect of antidepressant treatment.
sant medication.\textsuperscript{22} Weight data have been derived primarily from re-analysis of drug trials or cross-sectional observation data.\textsuperscript{26,27} Moreover, it appears that specific types of antidepressants, such as tricyclic antidepressants and mirtazapine, are more likely to induce weight gain.\textsuperscript{28}

Our data suggest that antidepressant treatment has a complex effect on BW regulation dependent on environmental factors. Under standard laboratory conditions and diet, non-stressed rats receiving chronic fluoxetine treatment weighed less than saline-treated controls, which is compatible with the literature.\textsuperscript{15} In our stress–antidepressant-diet study, animals submitted to RRS consumed fewer calories and were lighter during the stress period.

What is reported here as a novel finding is that animals that were given fat diet after the stress period ended achieved full weight recovery: the weights of non-treated animals (R-C, saline control group) were not significantly different from those of non-stressed animals receiving fat diet (NR-CF). In contrast, non-treated rats receiving regular chow and were lighter during the stress period.

To induce weight gain.\textsuperscript{28} lic antidepressants and mirtazapine, are more likely that specific types of antidepressants, such as tricyclic antidepressants, are more likely to induce weight gain.\textsuperscript{28}

Future studies should also address the role of stress and high-fat diets on long-term BW outcomes during and following antidepressant treatment in clinical
settings. It would be particularly important to understand whether long-term BW gain also occurs in animals fed with a variety of different diets, following exposure to stress and time-limited antidepressant treatment.

**Conflict of interest**

The authors declare no conflict of interest.

**Acknowledgments**

This research was supported in part by the National Institutes of Health Grant K24RR017365 to MLW, and by institutional funds from the University of Miami and The Australian National University. The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript. We thank Dr Sari Izenwasser for her invaluable help with behavioral experiments and setup.

**References**

1. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry* 2005; 62: 617–627.

2. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. *Arch Gen Psychiatry* 1994; 51: 8–19.

3. Vos T, Haby MM, Barendregt JJ, Kruijshaar M, Corry J, Andrews G. The burden of major depression avoidable by longer-term treatment strategies. *Arch Gen Psychiatry* 2004; 61: 1097–1103.

4. Lopez AD, Murray CC. The global burden of disease, 1990–2020. *Nat Med* 1998; 4: 1241–1243.

5. Bulloch AG, Patten SB. Non-adherence with psychotropic medications in the general population. *Soc Psychiatry Psychiatr Epidemiol* 2010; 45: 47–56.

6. Wang PS, Simon G, Kessler RC. The economic burden of depression and the cost-effectiveness of treatment. *Int J Methods Psychiatr Res* 2003; 12: 22–33.

7. Milane MS, Suchard MA, Wong ML, Licinio J. Modeling of the temporal patterns of fluoxetine prescriptions and suicide rates in the United States. *PLoS Med* 2006; 3: e190.

8. Olsson M, Marcus SC. National patterns in antidepressant medication treatment. *Arch Gen Psychiatry* 2009; 66: 848–856.

9. Mant A, Rendle VA, Hall WD, Mitchell PB, Montgomery WS, McManus PR et al. Making new choices about antidepressants in Australia: the long view 1975–2002. *Med J Aust* 2004; 181: S21–S24.

10. Moore M, Yuen HM, Dunn N, Mullee MA, Maskell J, Kendrick T. Explaining the rise in antidepressant prescribing: a descriptive study using the general practice research database. *BMJ* 2009; 338: b3999.

11. Olle JP, Elomari F, Spadone C, Lepine JP. Antidepressants consumption in the global population in France. *Encephale* 2002; 28: 411–417.

12. Papakostas GI. Limitations of contemporary antidepressants: tolerability. *J Clin Psychiatry* 2007; 68(Suppl E1): 8–13.

13. Serna MC, Cruz I, Real J, Gasco E, Galvan L. Duration and adherence of antidepressant treatment (2003 to 2007) based on prescription database. *Eur Psychiatry* 2010; 25: 206.
36 Atkinson T. Lifestyle drug market booming. *Nat Med* 2002; 8: 909.
37 Licinio J, Wong ML. Depression and obesity treatments are life saving. *Nat Med* 2002; 8: 1336.
38 CDC. *Behavioral Risk Factor Surveillance System Survey Data*. US Department of Health and Human Services, Centers for Disease Control and Prevention: Atlanta, GA, 2008.